Annotation Detail

Information
Associated Genes
GNA11
Associated Variants
GNA11 MUTATION
GNA11 MUTATION
Associated Disease
uveal melanoma
Source Database
CIViC Evidence
Description
A randomized phase II trial assessing the efficacy of Cabozantinib in metastatic melanoma. 77 patients (62% cutaneous, 30% uveal, 8% mucosal). Patients received cabozantinib 100 mg/d during a 12-week lead-in. Patients with stable disease (SD; RECIST) at week 12 were randomised to cabozantinib or placebo. During lead-in phase 55% of evaluable patients showed reduction in target lesion size (59% uveal melanoma). Uveal melanoma cohort included 23 patients, 9 with GNAQ (n=5) and GNA11 (n=4) mutations. Responses were reported in mutational patients. In the uveal melanoma cohort, 61% of patients (14/23) had SD at week 12, and no patient had a PR, resulting in an overall disease control rate of 61%. The median PFS for the 23 patients with uveal melanoma was 4.8 months.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/3049
Gene URL
https://civic.genome.wustl.edu/links/genes/2308
Variant URL
https://civic.genome.wustl.edu/links/variants/506
Rating
3
Evidence Type
Predictive
Disease
Uveal Melanoma
Evidence Direction
Supports
Drug
Cabozantinib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
28103611
Drugs
Drug NameSensitivitySupported
CabozantinibSensitivitytrue